$VBIO

Valion Bio (VBIO) is developing an oral mucosal formulation of Entolimod, a potential needle-free treatment for acute radiation syndrome (ARS). The company aims to address the growing need for scalable civilian radiation preparedness as nuclear power expands to support AI and data centers. Entolimod has shown promise in animal studies for both pre- and post-exposure protection. Valion believes this formulation could offer operational advantages in mass-casualty scenarios.

Valion Bio (VBIO) and Shear Kershman Labs completed formulation work on an oral mucosal version of Entolimod, a radiation drug. The oral formulation aims to offer a needle-free alternative to the injectable version, potentially improving scalability and distribution. Animal studies showed protection against radiation exposure, and the company believes this could support both military and civilian preparedness.

Valion Bio (VBIO) raised $50,000 in a private sale of Series B Preferred Shares and warrants to 3i. The deal includes 50 preferred shares and warrants for 1,539 common shares at $2.5520 per share. The funds will support liquidity and operations, according to the company's SEC filing.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B P

Valion Bio appointed Thomas Jensen as Board Chair. The company reported $35.6M in non-dilutive U.S. government funding for Entolimod, which has FDA Fast Track and Orphan Drug designations. Jensen may explore Entolimod's use in cancer supportive care.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government fund

Valion Bio completed an oral mucosal formulation of Entolimod using BioViscid™, potentially offering a needle-free delivery option. The company plans to study systemic exposure and pharmacokinetics. According to Valion, oral mucosal demand could be 10-40x injectable doses in a U.S. preparedness scenario.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimo

Valion Bio Inc. (VBIO) stock rose 23.68% after leadership changes and Nasdaq compliance. The company appointed Dean Zikria as interim CEO and Thomas Jensen as board chair. VBIO reported a quarterly loss of $7.1M, with $2.1M in cash and $28.2M in liabilities. The stock's volatility and high-risk profile are driven by its development-stage status and clinical trial news.

Valion Bio (VBIO) and Shear Kershman Labs (SKL) successfully formulated an oral mucosal version of Entolimod, a biologic for radiation protection. This could expand Entolimod's use beyond injectable forms, potentially increasing demand. Valion estimates a 10-40x larger market if the oral formulation is approved, targeting military and emergency personnel. The next step is testing systemic delivery. According to Valion, the injectable program remains a priority.